Early Phase Drug Evaluation in ManJohn O'Grady, Otto I Linet CRC Press, 2020 M02 3 - 737 pages Early Phase Drug Evaluation in Man is a comprehensive, practical guide that covers pre-clinical information relevant to early human studies, including pharmaceutical, metabolic, toxicological, and regulatory aspects, as well as the general considerations relevant to all early human studies. Each major therapeutic area is considered by class of activity of drug. The chapters describe what measurements of drug activity are available in healthy human subjects and in patients, how to make the measurements, their value and their limitations. The contributors have been drawn internationally from the pharmaceutical industry and academia. Early Phase Drug Evaluation in Man will provide an important reference guide for industry and academic professionals involved in the development of new drugs. |
From inside the book
Results 1-5 of 89
Page 10
... occur . Even when solutions with limited aqueous solubility are given via the oral route , they may precipitate in the stomach or intestinal region , because of either pH changes or solubility limitation , and then they must redissolve ...
... occur . Even when solutions with limited aqueous solubility are given via the oral route , they may precipitate in the stomach or intestinal region , because of either pH changes or solubility limitation , and then they must redissolve ...
Page 11
... occur ( Dighe , 1988 ) . Because of limitations in aqueous solubility , various solubilisation techni- ques may be investigated to increase the apparent solubility and achieve the desired formulation goal . Solubilisation techniques ...
... occur ( Dighe , 1988 ) . Because of limitations in aqueous solubility , various solubilisation techni- ques may be investigated to increase the apparent solubility and achieve the desired formulation goal . Solubilisation techniques ...
Page 12
... occur for most drugs and formulations in liquid or solid form . When drug formulations lose their potency by chemical degradation , the chemical potency should not fall below 90 % of the labelled storage condition . Physical appearance ...
... occur for most drugs and formulations in liquid or solid form . When drug formulations lose their potency by chemical degradation , the chemical potency should not fall below 90 % of the labelled storage condition . Physical appearance ...
Page 26
... occur may confound the interpretation of data and cause major problems in safety assessment . Although high dose administration may reveal the toxic potential of drugs , particularly affected target organs , it is very difficult to use ...
... occur may confound the interpretation of data and cause major problems in safety assessment . Although high dose administration may reveal the toxic potential of drugs , particularly affected target organs , it is very difficult to use ...
Page 35
... occur at high doses ( Glockin , 1981 ) . Pooled or individual specimens from mass balance studies can be used for this purpose . Elucidation of metabolic patterns during preclinical testing is essential for the expeditious ...
... occur at high doses ( Glockin , 1981 ) . Pooled or individual specimens from mass balance studies can be used for this purpose . Elucidation of metabolic patterns during preclinical testing is essential for the expeditious ...
Contents
Organisation and Decision Making | 97 |
Ethical and Legal Considerations | 137 |
Measuring Drug Activity in Man | 193 |
Assessment of Drug Effects on the Cardiovascular System ... | 251 |
Assessment of Drug Effects on the Respiratory System ... | 349 |
Assessment of Drug Effects on the Central Nervous System ... | 377 |
Assessment of Drug Effects on the Gastrointestinal System ... | 455 |
Assessment of Drug Effects on the Kidney | 493 |
Assessment of the Effects of Drugs Used in Obstetrics and Gynaecology ... | 519 |
Assessment of Drug Activity in the Skin | 551 |
Assessment of Drugs Used for the Treatment of Metabolic Disorders ... | 599 |
Assessment of the Effects of Chemotherapeutic Agents ... | 625 |
Assessment of Drugs Affecting the Inflammatory Process and Pain ... | 655 |
Index | 703 |
Other editions - View all
Common terms and phrases
absorption acid action activity acute administration adverse agents analgesic animal antidepressant anxiety anxiolytic assay assessment asthma benzodiazepines bioavailability biological blood pressure cardiac output cells changes chronic Clin clinical research clinical trials compound concentration consent coronary corticosteroids determine disease diuretics dosage dose drug development duration eczema effects of drugs efficacy enantiomers enzyme ethics committee evaluation excretion exercise experimental factors function gastric gastrointestinal gastrointestinal tract glucose guidelines healthy volunteers heart human important increase induced inhibition insulin intravenous investigator laboratory levels measurement metabolism metabolites method minoxidil monitoring myocardial normal NSAIDs oral pain parameters patients performed Pharm pharmaceutical pharmacodynamic pharmacokinetic pharmacological placebo plasma platelet potential preclinical predictive produce prostaglandin protocol receptor regulatory renal response rheumatoid arthritis risk safety scales Shuster side-effects skin specific studies subjects symptoms techniques therapeutic therapy tion tolerance toxicology treatment urine uterine visual analogue scales vitro vivo